查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433659

美國次要大麻素市場規模、佔有率和趨勢分析報告：按產品類型、應用和細分市場預測，2024-2030 年

U.S. Minor Cannabinoids Market Size, Share & Trends Analysis Report By Product (Cannabigerol (CBG), Tetrahydrocannabivarin (THCV), Cannabichromene (CBC)), By Application (Cancer, Inflammation, Neurological Disorders),& Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國次要大麻素市場成長與趨勢：

Grand View Research 的一項新研究顯示，到 2030 年，美國次要大麻素市場預計將達到 333 億美元。

預計2024年至2030年該市場將以15.0%的複合年成長率擴張。大麻素產品的使用不斷增加以及人們對大麻素消費帶來的健康益處的認知是支持成長的一些關鍵因素。

次要大麻素具有潛在的治療作用，包括發炎、鎮痛和神經保護作用。人們越來越有興趣開發含有少量大麻素的食品和營養補充，用於治療慢性疼痛、焦慮和睡眠障礙等各種疾病。例如，2021 年 1 月，Lygos, Inc. 宣布大麻環烯 (CBC) 的商業用途，它具有廣泛的益處，包括發炎、抗氧化和疼痛管理特性。

補充品、酊劑和外用藥等保健產品均含有少量大麻素。這些產品作為治療各種健康問題的自然療法進行銷售，並在尋求傳統藥物替代品的消費者中越來越受歡迎。例如，個人護理和健康保健產品供應商Nextraction提供其Kriva系列外用製劑，其中含有大麻酚(CBN)、大麻二酚酸(CBDA)和大麻二酚酸(CBGA)，並以可攝入的製劑形式釋放。

主要企業為加強其在美國次要大麻素行業的商機和足跡而進行的各種有機和無機開發預計將在預測期內推動市場擴張。 2022 年 10 月，生技公司 Purissima, Inc. 與 Open Book Extracts (OBX) 合作推出了首款發酵衍生的天然 CBC 產品，包括軟糖、外用精華液、酊劑和膠囊。

美國次要大麻素市場報告亮點：

  • 按產品類型分類，四氫大麻酚 (THCV) 細分市場佔據主導地位，2023 年銷售佔有率為 25.9%。這是由於 THCV 在治療關節炎、代謝失調和癲癇等疾病方面的應用越來越多。
  • 按應用來看，由於神經系統疾病盛行率不斷上升以及大麻素在其治療中的應用，神經系統疾病細分市場在 2023 年將佔據重要的收益佔有率。
  • 主要市場參與者：GCM Holdings (Global Cannabinoids), LLC、GenCanna、Mile High Labs、ZERO POINT EXTRACTION, LLC、BulKanna、CBD.INC。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國次要大麻素市場：變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國次要大麻素市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國小規模大麻素市場：產品類型估算與趨勢分析

  • 2023 年及 2030 年產品類型市場佔有率
  • 細分儀表板
  • 按產品類型分類的美國次要大麻素市場前景
  • 2018年至2030年市場規模、預測與趨勢分析

第5章美國次要大麻素市場：使用量估計與趨勢分析

  • 2023年及2030年應用市場佔有率
  • 細分儀表板
  • 美國次要大麻素市場前景（按應用）
  • 2018年至2030年市場規模、預測與趨勢分析

第6章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • Mile High Labs
    • GCM Holdings, LLC
    • GenCanna.
    • CBD. INC.
    • Rhizo Sciences
    • Laurelcrest
    • Fresh Bros Hemp Company
    • BulKanna
    • High Purity Natural Products
    • ZERO POINT EXTRACTION, LLC
Product Code: GVR-4-68039-683-5

U.S. Minor Cannabinoids Market Growth & Trends:

The U.S. minor cannabinoids market size is expected to reach USD 33.3 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.0% from 2024 to 2030. Rising use of cannabinoid-based products and awareness regarding the health benefits associated with cannabinoid consumption are some of the crucial factors supporting the growth.

Minor cannabinoids have potential therapeutic benefits, including anti-inflammatory, analgesic, and neuroprotective effects. There is a growing interest in developing pharmaceuticals and nutraceuticals containing minor cannabinoids for the treatment of various medical conditions, such as chronic pain, anxiety, and sleep disorders. For instance, in January 2021, Lygos, Inc. announced the commercial availability of cannabichromene (CBC) that has a wide range of anti-inflammatory, antioxidant, and pain management properties.

Wellness products such as supplements, tinctures, and topicals incorporate minor cannabinoids. These products are marketed as natural remedies for various health issues, and are becoming popular among consumers who are looking for alternatives to traditional medications. For instance, Nextraction, a supplier of personal care and health & wellness products, launched Kriva-a range of Cannabinol (CBN), cannabidiol acid (CBDA), and Cannabigerolic acid (CBGA)-in topical and ingestible formulas.

Various organic and inorganic developments done by key players to strengthen their business avenues and footprints in the U.S. minor cannabinoids industry are anticipated to facilitate market expansion over the forecast period. In October 2022, Purissima, Inc., a biotechnology company in partnership with Open Book Extracts (OBX), launched its first fermentation-derived natural CBC products such as gummies, topical serums, tinctures, and capsules.

U.S. Minor Cannabinoids Market Report Highlights:

  • Based on product type, the tetrahydrocannabivarin (THCV) segment dominated the market with a revenue share of 25.9% in 2023, owing to increasing application of THCV in the management of conditions such as arthritis, metabolic disorders, and epilepsy
  • Based on application, the neurological disorders segment accounted for a significant revenue share in 2023, due to the rising prevalence of neurological disorders and applications of cannabinoids in their management
  • Some of the major market players include GCM Holdings (Global Cannabinoids), LLC, GenCanna, Mile High Labs, ZERO POINT EXTRACTION, LLC, BulKanna, and CBD. INC.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Application
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product type outlook
    • 2.2.2. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Minor Cannabinoids Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Minor Cannabinoids Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Minor Cannabinoids Market: Product Type Estimates & Trend Analysis

  • 4.1. Product Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Minor Cannabinoids Market by Product Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Cannabigerol (CBG)
      • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Cannabichromene (CBC)
      • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Cannabinol (CBN)
      • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Tetrahydrocannabivarin (THCV)
      • 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Cannabigerolic acid (CBGA)
      • 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Minor Cannabinoids Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global U.S. Minor Cannabinoids Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Inflammation
      • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Pain Management
      • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Neurological Disorders
      • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Cancer
      • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Mile High Labs
      • 6.3.1.1. Company overview
      • 6.3.1.2. Financial performance
      • 6.3.1.3. Product benchmarking
      • 6.3.1.4. Strategic initiatives
    • 6.3.2. GCM Holdings, LLC
      • 6.3.2.1. Company overview
      • 6.3.2.2. Financial performance
      • 6.3.2.3. Product benchmarking
      • 6.3.2.4. Strategic initiatives
    • 6.3.3. GenCanna.
      • 6.3.3.1. Company overview
      • 6.3.3.2. Financial performance
      • 6.3.3.3. Product benchmarking
      • 6.3.3.4. Strategic initiatives
    • 6.3.4. CBD. INC.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Rhizo Sciences
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. Laurelcrest
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Fresh Bros Hemp Company
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. BulKanna
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. High Purity Natural Products
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. ZERO POINT EXTRACTION, LLC
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. minor cannabinoids market, by product type, 2018 - 2030 (USD Million)
  • Table 3 U.S. minor cannabinoids market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. minor cannabinoids market: market outlook
  • Fig. 9 U.S. minor cannabinoids competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. minor cannabinoids market driver impact
  • Fig. 15 U.S. minor cannabinoids market restraint impact
  • Fig. 16 U.S. minor cannabinoids market strategic initiatives analysis
  • Fig. 17 U.S. minor cannabinoids market: Product type movement analysis
  • Fig. 18 U.S. minor cannabinoids market: Product type outlook and key takeaways
  • Fig. 19 Cannabigerol (CBG)market estimates and forecast, 2018 - 2030
  • Fig. 20 Cannabichromene (CBC) market estimates and forecast, 2018 - 2030
  • Fig. 21 Cannabinol (CBN) market estimates market and forecast, 2018 - 2030
  • Fig. 22 Tetrahydrocannabivarin (THCV) market estimates and forecast, 2018 - 2030
  • Fig. 23 Cannabigerolic acid (CBGA) market estimates and forecast, 2018 - 2030
  • Fig. 24 Others (Cannabidiolic Acid (CBDA), Cannabidivarin (CBDV), And Other Minor Cannabinoids) estimates and forecast, 2018 - 2030
  • Fig. 25 U.S. minor cannabinoids market: Application movement Analysis
  • Fig. 26 U.S. minor cannabinoids market: Application outlook and key takeaways
  • Fig. 27 Inflammation market estimates and forecasts, 2018 - 2030
  • Fig. 28 Pain management market estimates and forecasts, 2018 - 2030
  • Fig. 29 Neurological disorders market estimates and forecasts,2 018 - 2030
  • Fig. 30 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030